What is he best known for?
The fields of study he is best known for:
- Gene
- Cancer
- Internal medicine
Jacques J.M. van Dongen mainly investigates Immunology, Molecular biology, Gene rearrangement, B cell and Minimal residual disease.
His is doing research in Antigen, Antibody, CD19, Immunophenotyping and Immune system, both of which are found in Immunology.
His Molecular biology research incorporates themes from Dendritic cell, Recombination-activating gene, RAG2 and Gene, Severe combined immunodeficiency.
The various areas that he examines in his Gene rearrangement study include Cellular differentiation, T cell, T-cell receptor, Regulation of gene expression and Polymerase chain reaction.
His B cell research is multidisciplinary, incorporating elements of DNA and Immunoglobulin heavy chain.
His study in Minimal residual disease is interdisciplinary in nature, drawing from both Flow cytometry, Acute lymphocytic leukemia and Oncology.
His most cited work include:
- Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood (851 citations)
- Immunophenotyping of blood lymphocytes in childhood: Reference values for lymphocyte subpopulations (594 citations)
- Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study (509 citations)
What are the main themes of his work throughout his whole career to date?
Immunology, Molecular biology, Antibody, Internal medicine and Immunophenotyping are his primary areas of study.
His work in B cell, Bone marrow, Immune system, EuroFlow and Antigen are all subfields of Immunology research.
In his study, Polymerase chain reaction is inextricably linked to Gene rearrangement, which falls within the broad field of Molecular biology.
Jacques J.M. van Dongen has researched Internal medicine in several fields, including Surgery and Oncology.
In Immunophenotyping, he works on issues like Leukemia, which are connected to Cancer research.
The study incorporates disciplines such as Acute lymphocytic leukemia and Transplantation in addition to Minimal residual disease.
He most often published in these fields:
- Immunology (42.63%)
- Molecular biology (22.12%)
- Antibody (19.23%)
What were the highlights of his more recent work (between 2017-2021)?
- Immunophenotyping (17.95%)
- Immunology (42.63%)
- Flow cytometry (10.90%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Immunophenotyping, Immunology, Flow cytometry, EuroFlow and Antibody.
His research integrates issues of Cancer research, Leukemia and Bone marrow in his study of Immunophenotyping.
His Flow cytometry research is multidisciplinary, relying on both Myeloid, Pathology, Lymphocyte, Tissue damage and Multiple myeloma.
His research in EuroFlow intersects with topics in Orientation, Newborn screening and Acute leukemia.
Jacques J.M. van Dongen specializes in Antibody, namely B cell.
His B cell research integrates issues from Second line treatment, Chronic lymphocytic leukemia, Melphalan and Minimal residual disease.
Between 2017 and 2021, his most popular works were:
- Age-associated distribution of normal B-cell and plasma cell subsets in peripheral blood (63 citations)
- Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study (55 citations)
- Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma (44 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
The scientist’s investigation covers issues in Internal medicine, Oncology, Minimal residual disease, EuroFlow and Flow cytometry.
His Internal medicine study integrates concerns from other disciplines, such as Text mining and Fusion gene.
His studies in Oncology integrate themes in fields like Survival rate, Clinical endpoint, Randomized controlled trial and Surrogate endpoint.
His Minimal residual disease research is multidisciplinary, incorporating perspectives in Progression-free survival, Chemoimmunotherapy, Primer, Computational biology and DNA sequencing.
His work in Flow cytometry addresses subjects such as Cancer research, which are connected to disciplines such as Immunophenotyping.
Jacques J.M. van Dongen integrates Viral pathogenesis with Immunology in his research.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
